Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.
We evaluated the use of a simple and easy-to-obtain potential marker of tuberculosis (TB) drug efficacy, body weight, and correlated weight loss or gain with the number of CFU of Mycobacterium tuberculosis in lungs and spleens of infected mice. C3H mice were infected intravenously with 10(6) CFU of virulent M. tuberculosis H37Rv, and body weight was evaluated for several weeks after infection. At day 20, infected untreated mice consistently lost more than 25% of their body weight. Chemotherapy with selected orally active anti-TB drugs was initiated 7 days following infection and continued for 13 days. Drugs that were administered daily by gavage included isoniazid (INH), ethambutol (EMB), rifampin (RIF), and moxifloxacin (MXF). At the most effective doses, each of these drugs inhibited bacterial growth and abolished infection-induced body weight loss. Chemotherapy with 1/10 the standard dose of INH determined in accepted long-term murine models of TB also prevented body weight loss, while chemotherapy with 1/10 the standard dose of RIF did not. With only 2 weeks of chemotherapy, we observed a good reverse correlation between CFU in lung or spleen and body weight of mice. The simple measurement of weight in TB-infected drug-treated mice required only a weight balance, and go/no-go drug efficacy data was available on day 20 without the necessity of prolonged drug treatment and long (3 weeks or more) in vitro culture times to obtain organ CFU values.
Nikonenko
Boris V
BV
Sequella, Inc., Rockville, Maryland 20850, USA. borisnikonenko@sequella.com
Samala
Rowena
R
Einck
Leo
L
Nacy
Carol A
CA
D000818:Animals; D000995:Antitubercular Agents / Q000494:pharmacology*; D003114:Colony-Forming Units Assay; D004353:Drug Evaluation, Preclinical; D005260:Female; D007538:Isoniazid / Q000494:pharmacology; D008168:Lung / Q000382:microbiology; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D012293:Rifampin / Q000494:pharmacology; D013154:Spleen / Q000382:microbiology; D014376:Tuberculosis / Q000188:drug therapy / Q000382:microbiology; D015431:Weight Loss
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin